Clinical trials
Efficacy and Safety clinical trials
Below are recruiting efficacy and safety clinical trials, each written for real people, not researchers. We’re tracking 2,733 recruiting studies, each written for real people, not researchers, below.
Recruiting studies
- NCT06328712RecruitingPhase 1/Phase 2
Cell therapy for Charcot-Marie-Tooth type 1A (CMT1A)
This trial tests a new cell therapy called EN001 for people with CMT1A. It aims to see if the treatment is safe and can help with nerve function and muscle weakness.
GyeongjuAges 19 years+ - NCT06326411RecruitingPhase 1
Testing NST-628 pills for advanced solid tumors with RAS/MAPK changes
This trial tests an experimental pill called NST-628 for people with advanced solid tumors that have specific genetic changes in the RAS/MAPK pathway. The goal is to see if it is safe and effective when other treatments are no longer working.
San Francisco, CaliforniaAges 18 years+ - NCT06330064RecruitingPhase 1/Phase 2
Study of a new drug for advanced solid tumors
This study tests a new drug called Ifinatamab Deruxtecan (I-DXd) for people with several types of advanced cancer that has grown despite standard treatments. The drug is designed to target and attack cancer cells directly, potentially shrinking tumors or slowing their growth.
Los Angeles, CaliforniaAges 18 years+ - NCT06335160Recruiting
Mebendazole for mild to moderate ulcerative colitis
This study tests adding a medicine called mebendazole (normally used for parasites) to standard mesalamine treatment for people with mild or moderate ulcerative colitis. The goal is to see if it helps control inflammation better than mesalamine alone.
TantaAges 18–75 - NCT06326476RecruitingEarly Phase 1
Siplizumab injection for moderate to severe hidradenitis suppurativa
This study tests an injected drug called siplizumab for people with moderate to severe hidradenitis suppurativa (HS) that hasn't improved with other treatments. The goal is to see if it safely reduces painful bumps and improves your skin condition.
Birmingham, AlabamaAges 18 years+ - NCT06313801RecruitingPhase 2
Chemotherapy with or without PIPAC for stomach cancer
This trial tests whether adding a special type of chemotherapy sprayed directly into the abdomen (PIPAC) to standard chemotherapy is safer and works better for stomach cancer that has spread only to the lining of the abdomen.
Nizhny NovgorodAges 18–75 - NCT06311682RecruitingPhase 3
Testing a new shot plus steroid cream for children with eczema
This study tests an investigational shot (tralokinumab) plus a steroid cream for children with moderate-to-severe eczema that hasn't been controlled by creams alone. It aims to see if the combination is safe and works better than the cream alone.
Birmingham, AlabamaAges 6 months–11 years - NCT06312137RecruitingPhase 3
Pembrolizumab with or without another drug for lung cancer after surgery
This trial tests adding a new drug (sacituzumab tirumotecan) to pembrolizumab for people with non-small cell lung cancer that did not completely disappear after initial treatment and surgery. The goal is to see if the combination works better than pembrolizumab alone.
Little Rock, ArkansasAges 18 years+ - NCT06304103RecruitingPhase 2
Study of AND017 for low-risk myelodysplastic syndrome
This trial tests an experimental drug called AND017 for people with a certain type of myelodysplastic syndrome (MDS) that is low-risk and not linked to a chromosome 5 deletion. The goal is to see if AND017 can help improve low red blood cell counts (anemia) and reduce or avoid the need for blood transfusions.
Hangzhou, ZhejiangAges 18–75 - NCT06305949Recruiting
Brain stimulation to improve swallowing after stroke
This trial tests a gentle electrical brain stimulation (tDCS) to see if it helps improve swallowing after a first-time stroke. It is designed for people who are at least 3 weeks post-stroke and still have swallowing problems.
Bucheon-siAges 19 years+ - NCT06307665RecruitingPhase 3
Asthma study for teens comparing two inhalers
This study tests a new inhaler (PT027) against another inhaler (PT007) for teens aged 12 to 17 with asthma. It looks at how well the new inhaler works when used as needed, and if it is safe.
Anchorage, AlaskaAges 12–17 - NCT06295614Recruiting
ARC-IM therapy for walking problems in Parkinson's
This study tests a new therapy called ARC-IM to help with walking issues like freezing or balance problems in people with Parkinson's. It aims to see if the therapy is safe and can improve movement.
Lausanne, Canton of VaudAges 18 years+ - NCT06306300RecruitingPhase 4
Hepatitis C treatment at local clinics vs standard care
This study compares two ways to treat hepatitis C: getting treatment at a local clinic near you, or the usual care at a central hospital. It aims to see if treatment at local clinics is safe, effective, and more convenient for patients.
Rio de Janeiro, Rio de JaneiroAges 18–79 - NCT05116072RecruitingPhase 1/Phase 2
Islet cell transplant plus surgery for high fistula risk
This Phase 1/2 study tests whether adding an islet (insulin-producing cell) transplant at the time of pancreatic-region surgery is safe and helps prevent a serious surgical complication called a postoperative fistula. It is for people whose surgery is considered high risk for developing that complication.
LilleAges 18 years+ - NCT06281964Enrolling by invitationPhase 3
New pill for EGFR Exon 20 lung cancer
This study tests a new pill called PLB1004 for people whose lung cancer has a specific EGFR mutation (exon 20 insertion). It is for those who have not yet had any treatment for their advanced cancer.
Guangzhou, GuangzhouAges 18 years+ - NCT06292650RecruitingEarly Phase 1
Gene therapy ZM-02 for advanced retinitis pigmentosa
This experimental gene therapy (ZM-02) is designed for people with advanced retinitis pigmentosa who have very poor vision (counting fingers or worse). It aims to see if the treatment is safe and can improve vision by replacing a faulty gene in the retina.
Beijing, Beijing MunicipalityAges 18–65 - NCT06278454RecruitingPhase 1
Radioactive injection for advanced pancreatic cancer
This trial tests a new radioactive injection called NRT6008 for people with pancreatic cancer that cannot be surgically removed. It aims to see if the treatment can shrink the tumor and improve survival.
Zhengzhou, HenanAges 18–80 - NCT06290141RecruitingPhase 3
Testing riliprubart vs. standard IVIg for CIDP
This trial tests whether a new medication called riliprubart works as well as the usual IVIg treatment for people with chronic inflammatory demyelinating polyneuropathy (CIDP). It may offer another option for managing your condition.
Homewood, AlabamaAges 18 years+ - NCT06282575RecruitingPhase 3
Zanidatamab plus chemo for advanced HER2-positive bile duct cancer
This phase 3 trial tests whether adding zanidatamab (a targeted antibody) to standard chemotherapy can improve outcomes for advanced HER2-positive biliary tract cancer. If you have this type of cancer that has spread or can't be removed, and you've had little or no prior treatment, this study might be an option.
Duarte, CaliforniaAges 18 years+ - NCT06289478Recruiting
Tranexamic acid for bleeding during hip replacement surgery
This study tests whether a medicine called tranexamic acid (TXA), given as a shot into the hip joint or as a soak on the skin, can reduce bleeding during hip replacement surgery. It is for people over 60 who broke their hip from a simple fall and need a cementless hip replacement.
Bangkok, BangkokAges 60 years+ - NCT06275516Recruiting
Virtual Reality with Sights, Sounds, and Touch for Stroke Recovery
This study tests whether a special virtual reality program that uses sights, sounds, and touch can help people who have had a stroke move their leg better. You might qualify if you had a first stroke, have trouble moving your leg, and can walk a little bit with help.
Chongqing, Chongqing MunicipalityAges 18–85 - NCT06291025Recruiting
Testing a simpler treatment for immune-mediated TTP
This study is testing a new combination of medicines—immune-suppressing drugs, caplacizumab, and plasma infusions—to treat immune-mediated TTP without standard plasma exchange. It aims to make treatment simpler and potentially safer.
AmiensAges 18 years+ - NCT06282965RecruitingPhase 1/Phase 2
Angiotensin (1-7) for moderate to severe brain injury
This study tests a drug called Angiotensin (1-7) to see if it helps people recover from moderate to severe traumatic brain injury. It may reduce damage and improve healing when given shortly after the injury.
Tucson, ArizonaAges 18 years+ - NCT06264531RecruitingPhase 2/Phase 3
Bevacizumab for adults with symptomatic, untreatable brain AVMs
This trial tests a medication called bevacizumab (given as an IV infusion) to see if it can improve symptoms in people with brain arteriovenous malformations (AVMs) that cannot be treated with standard therapies. It is for those whose AVMs cause significant disability.
Paris, Île-de-France RegionAges 18 years+
Hear when a new Efficacy and Safety trial opens
We’ll email you when one opens — at most once a week, no account needed, unsubscribe anytime.
Common questions
- Are there clinical trials for efficacy and safety?
- Yes. Clin2 currently lists 2,733 recruiting efficacy and safety studies from the U.S. registry, each rewritten for real people, not researchers, so you can see what it’s testing and who it’s for.
- How do I know if I qualify for a efficacy and safety trial?
- Each study lists its eligibility criteria — rules about age, diagnosis, and prior treatments. On every Clin2 trial page we explain these in words written for real people and offer a short, optional pre-screen for a fit read. The study team makes the final decision.
- Does it cost anything to join a efficacy and safety trial?
- Using Clin2 is always free. Many trials cover the cost of the study treatment and related visits; some reimburse travel. The study team explains exactly what’s covered before you decide.
Related conditions
Clin2 helps you find and understand clinical trials and does not provide medical advice. Study data comes from ClinicalTrials.gov. Talk with your doctor about whether a specific trial is right for you.